<p>百时美施贵宝公司周五公布了第二季度业绩，超过了分析师的预期，因为该公司一些较新的药物开始表现出色。百时美施贵宝（BMY）报告了强于预期的第二季度业绩，展示了其较新药物艾力昔和奥帕利的强劲表现。公司的盈利超过预期，营收增长导致全年指引显著增加。</p>
<p>第二季度对于 BMY 来说是一个令人印象深刻的成就，调整后的每股盈利（EPS）达到 2.07 美元，超过了分析师预期的 1.63 美元。营收也超出预期，达到 122 亿美元，而预期为 115.4 亿美元。</p>
<p>BMY 增长的主要贡献者之一是艾力昔，一种抗凝血药物，全球营收同比增长 7%，达到 34.2 亿美元。该药物的出色表现得益于其在美国的强劲销售，美国市场创造了超过 25 亿美元的营收。</p>
<p>BMY 的另一个亮点是奥帕利，一种癌症药物，营收同比增长 11%，达到近 24 亿美元。这种增长组合药物的强劲表现展示了 BMY 较新治疗方案的潜力。</p>
<p>公司令人印象深刻的第二季度业绩导致全年指引显著增加。BMY 现在预计 2024 年调整后营收将在之前预期的低个位数百分比增长的较高端上升。调整后的每股盈利指引也提高，公司现在预计范围为 0.60 至 0.90 美元，而之前的范围为 0.40 至 0.70 美元。</p>
<p>BMY 股票对第二季度业绩做出积极回应，截至周五上午 10:30，股价上涨近 8%，达到 48.77 美元。</p>
<p>参考文献：</p>
<p>[1] &#34;Bristol-Myers Squibb's second-quarter results beat revenue and adjusted EPS expectations, boosting guidance on rising drug sales.&#34; Investopedia.2022 年 7 月 14 日。https://www.investopedia.com/bristol-myers-squibb-beats-q2-expectations-boosts-guidance-on-rising-drug-sales-8684316</p>

百时美施贵宝

<p>百时美施贵宝（BMY）发布了强于预期的第二季度业绩报告，每股收益超过预期，营收也超过了预期。公司的新药 Eliquis 和 Opdivo 为其增长做出了贡献。因此，百时美施贵宝提高了全年调整后营收和每股收益的指引。BMY 的股价也对这一消息做出了积极反应，股价上涨近 8%</p>

<p>Bristol Myers Squibb Co. on Friday reported second-quarter results that topped analysts’ estimates as some of the company’s newer drugs began to hit their stride.Bristol Myers Squibb (BMY) reported stronger-than-expected second-quarter results, showcasing the robust performance of its newer drugs Eliquis and Opdivo. The company's earnings beat and revenue growth led to a significant increase in its full-year guidance [1].</p>
<div class="lb-trans"><p>百时美施贵宝公司周五公布了第二季度业绩，超过了分析师的预期，因为该公司一些较新的药物开始表现出色。百时美施贵宝（BMY）报告了强于预期的第二季度业绩，展示了其较新药物艾力昔和奥帕利的强劲表现。公司的盈利超过预期，营收增长导致全年指引显著增加。</p>
</div><p>The second quarter marked an impressive feat for BMY, with adjusted earnings per share (EPS) coming in at $2.07, surpassing analysts' expectations of $1.63 [1]. Revenue also exceeded estimates, reaching $12.2 billion compared to the projected $11.54 billion [1].</p>
<div class="lb-trans"><p>第二季度对于 BMY 来说是一个令人印象深刻的成就，调整后的每股盈利（EPS）达到 2.07 美元，超过了分析师预期的 1.63 美元。营收也超出预期，达到 122 亿美元，而预期为 115.4 亿美元。</p>
</div><p>One of the primary contributors to BMY's growth was Eliquis, a blood thinner drug that experienced a 7% year-over-year increase in worldwide revenue, reaching $3.42 billion [1]. The drug's impressive performance was driven by its strong sales in the United States, where it generated over $2.5 billion in revenue [1].</p>
<div class="lb-trans"><p>BMY 增长的主要贡献者之一是艾力昔，一种抗凝血药物，全球营收同比增长 7%，达到 34.2 亿美元。该药物的出色表现得益于其在美国的强劲销售，美国市场创造了超过 25 亿美元的营收。</p>
</div><p>Another standout for BMY was Opdivo, a cancer drug that recorded an 11% year-over-year increase in revenue, amounting to nearly $2.4 billion [1]. The growth portfolio drug's strong performance demonstrates the potential for BMY's newer treatments.</p>
<div class="lb-trans"><p>BMY 的另一个亮点是奥帕利，一种癌症药物，营收同比增长 11%，达到近 24 亿美元。这种增长组合药物的强劲表现展示了 BMY 较新治疗方案的潜力。</p>
</div><p>The company's impressive second-quarter results led to a significant increase in its full-year guidance. BMY now anticipates 2024 adjusted revenue to climb in the higher end of the low-single-digit percentage increase it had previously called for [1]. Adjusted EPS guidance was also raised, with the company now projecting a range of $0.60 to $0.90, up from the previous range of $0.40 to $0.70 [1].</p>
<div class="lb-trans"><p>公司令人印象深刻的第二季度业绩导致全年指引显著增加。BMY 现在预计 2024 年调整后营收将在之前预期的低个位数百分比增长的较高端上升。调整后的每股盈利指引也提高，公司现在预计范围为 0.60 至 0.90 美元，而之前的范围为 0.40 至 0.70 美元。</p>
</div><p>Shares of BMY responded positively to the second-quarter results, with the stock climbing nearly 8% to $48.77 as of 10:30 a.m. on Friday [1].</p>
<div class="lb-trans"><p>BMY 股票对第二季度业绩做出积极回应，截至周五上午 10:30，股价上涨近 8%，达到 48.77 美元。</p>
</div><p>References:</p>
<p>[1] &#34;Bristol-Myers Squibb's second-quarter results beat revenue and adjusted EPS expectations, boosting guidance on rising drug sales.&#34; Investopedia. 14 July 2022. https://www.investopedia.com/bristol-myers-squibb-beats-q2-expectations-boosts-guidance-on-rising-drug-sales-8684316</p>
<div class="lb-trans"><p>参考文献：</p>
<p>[1] &#34;Bristol-Myers Squibb's second-quarter results beat revenue and adjusted EPS expectations, boosting guidance on rising drug sales.&#34; Investopedia.2022 年 7 月 14 日。https://www.investopedia.com/bristol-myers-squibb-beats-q2-expectations-boosts-guidance-on-rising-drug-sales-8684316</p>
</div>

由于新药带来了增长，百时美施贵宝的业绩超出预期